Newsroom | 8835 results

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the Compensation Committee of its Board of Directors has granted equity awards to two new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity award...

CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced the U.S. launch of the next generation LifeVest® wearable cardioverter defibrillator (WCD). This marks the fifth FDA-approved LifeVest WCD, which works seamlessly with the recently launched next generation LifeVest WCD garment, the most comfortable LifeVest WCD ever.1 Backed by decades of continuous innovation informed by patient feedback, LifeVest contin...

WHITMORE LAKE, Mich.--(BUSINESS WIRE)--Trace Medical, the national leader in advanced respiratory rentals and biomedical services has announced an equity investment in LiViliti Health Products Inc., an innovator of CPAP and respiratory accessories, based in Sarasota, Florida. Greg Apostolou, Chief Executive Officer of Trace Medical, stated “LiViliti and Trace are a natural fit, leveraging LiViliti’s suite of health cleaning products and core expertise with Trace Medical’s infrastructure and mar...

SUNNYVALE, Calif.--(BUSINESS WIRE)--EBR Systems, Inc., developer of the world’s only left ventricular wireless cardiac pacing device for heart failure, today announced that management will be presenting at the J.P. Morgan 2026 Healthcare Conference on Thursday, January 15, 2026, at the Westin St. Francis in San Francisco, CA. About EBR Systems EBR Systems is a cardiac rhythm management company on a clear mission: to transform the lives of people with heart failure by helping physicians deliver...

WASHINGTON--(BUSINESS WIRE)--New national and state data released today by the Partnership to Fight Chronic Disease (PFCD) projects that chronic disease is on pace to cost the United States as much as $47 trillion between 2024 and 2039, including $2.2 trillion annually in medical costs and nearly $900 billion each year in lost productivity by 2039. The analysis, conducted by GlobalData, highlights a stark reality: 5% of people account for nearly 50% of total health care spending, driven largely...

DUBLIN, Ohio--(BUSINESS WIRE)--US Heart & Vascular (USHV), a leading national cardiovascular physician practice management organization, today announced a strategic collaboration with FillPoint Health, a Lyceum Company and URAC/ACHC-accredited Specialty Pharmacy and Management Services Organization (MSO), and Corstasis Therapeutics to improve access, adherence, and patient outcomes in the management of heart failure. Under this collaboration, FillPoint Health will serve as the preferred spe...

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS), today announced completion of a productive in-person pre-IND meeting with the United States Food and Drug Administration (FDA) for a planned study evaluating DM199 in preeclampsia. Minutes from the meeting affirmed the FDA’s request for one additional non-clinical, 1...

PASADENA, Calif.--(BUSINESS WIRE)--New study shows that non-invasive Vivio System is more accurate than blood tests and echocardiography for early detection of heart failure....

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026. Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT. Scott Ullem, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived ve...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the Company’s Investigational Device Exemption (IDE), allowing Pulse Biosciences to proceed with the initiation of its nPulse Cardiac Catheter Ablation System Study (NANOPULSE-AF) for the treatm...